This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
Just a few days after PerkinElmer officials said that the firm’s acquisition priorities begin with expanding its genetic testing business, the firm this week agreed to buy ViaCell, a Cambridge, Mass.-based specialty stem cell company, for around $300 million.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.